Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Ghia P, Barr PM, Allan JN, et al. Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin ...

Travel barriers and lack of local sites hinder clinical trial enrollment for underserved patients, and decentralizing trials is key to improving access, according to Mariam Eskander, MD, MPH.

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Living in food deserts, clinical trial deserts, and areas with high transportation vulnerability significantly lowers breast ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.